Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors
Clinical trial NCT01673438 · COMPLETED
Trial details
- NCT number
- NCT01673438
- Sponsor
- ImmunityBio, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-07-01
- Primary completion
- 2014-04-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.